Although NPM1 mutated AML patients with a low FLT3-ITD allelic ratio tended to have a lower CIR compared to all other patients (p = 0.09), there were no significant outcome differences according to the NPM1 mutation and FLT3-ITD allelic ratio combinations (EFS p = 0.60, Figure 3B; CIR p = 0.36 and OS p = 0.60, Supplementary Figure S5C,D). The gene discussed is NPM1; the disease is acute myeloid leukemia.